Top

16-05-2024 | Ketamine | Review

Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review

Authors: Alisha M. Bruton, Dalton G. Wesemann, Taryn A. Machingo, Gop Majak, Jeanette M. Johnstone, Rebecca D. Marshall

Published in: European Child & Adolescent Psychiatry

Abstract

Mood disorders, anxiety, and suicidality in youth are increasing and rapid-acting treatments are urgently needed. One potential is ketamine or its enantiomer esketamine, which was FDA approved in 2019 to treat major depressive disorder with suicidality in adults. This systematic review evaluated the evidence for the clinical use of ketamine to treat mood disorders, anxiety, and suicidality in youth. The PRISMA guidelines were used, and a protocol registered prospectively (https://osf.io/9ucsg/). The literature search included Pubmed/MEDLINE, Ovid/MEDLINE, Scopus, CINAHL, PsychInfo, and Google Scholar. Trial registries and preprint servers were searched, and authors contacted for clarification. Studies reported on the clinical use of ketamine to treat anxiety, depression, bipolar disorder, or suicidality in youth ≤19 years old and assessed symptoms before and after ketamine use. Study screening and data extraction were conducted independently by 2–4 authors. Safety, tolerability, and efficacy data were collected. The Cochrane Risk of Bias guidelines assessed the quality of the evidence. Twenty-two published reports based on 16 studies were identified: 7 case studies, 6 observational studies, 3 randomized trials, and 6 secondary data analyses. Studies reported immediate improvements in depression, anxiety, and suicidality. Improvements were maintained for weeks-months following treatment. Ketamine was well-tolerated with the most common side effects being dizziness, nausea, and mild dissociation. Transient hemodynamic changes were reported, all of which resolved quickly and did not require medical intervention. Initial evidence suggests ketamine is safe and may be effective for mood disorders, anxiety, and suicidality in youth. Further randomized trials are warranted.

Available only for authorised users

(2021) Key substance use and mental health indicators in the United States: results from the 2021 national survey on drug use and health. Substance Abuse and Mental Health Services Administrstion, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration

Goldstein BI, Birmaher B (2012) Prevalence, clinical presentation, and differential diagnosis of pediatric bipolar disorder. Isr J Psychiatry Relat Sci 49:3–14PubMedPubMedCentral

Torio CM, Encinosa W, Berdahl T, McCormick MC, Simpson LA (2015) Annual report on health care for children and youth in the United States: national estimates of cost, utilization and expenditures for children with mental health conditions. Acad Pediatr 15:19–35. https://doi.org/10.1016/j.acap.2014.07.007CrossRefPubMed

Centers for Disease Control (2023) Facts about suicide. In: Facts suicide. https://www.cdc.gov/suicide/facts/index.html. Accessed 4 Oct 2023

Gaylor EM, Krause KH, Welder LE, Cooper AC, Ashley C, Mack KA, Crosby AE, Trinh E, Ivey-Stephenson AZ, Whittle L (2023) Suicidal thoughts and behaviors among high school students—youth risk behavior survey, United States, 2021. MMWR Suppl 2:45–54. https://doi.org/10.15585/mmwr.su7201a6CrossRef

Chang L, Rajagopalan S, Mathew S (2016) The history of ketamine use and its clinical indications. In: Ketamine for treatment-resistant depression: the first decade of progress. Adis, Cham, pp 1–12

Rosenbaum SB, Gupta V, Patel P, Palacios JL (2023) Ketamine. In: StatPearls. StatPearls Publishing, Treasure Island

Jelen LA, Young AH, Stone JM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol Oxf Engl 35:109–123. https://doi.org/10.1177/0269881120959644CrossRef

Siegel AN, Di Vincenzo JD, Brietzke E, Gill H, Rodrigues NB, Lui LMW, Teopiz KM, Ng J, Ho R, McIntyre RS, Rosenblat JD (2021) Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: a systematic review. J Psychiatr Res 137:426–436. https://doi.org/10.1016/j.jpsychires.2021.03.009CrossRefPubMed

10.

Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE (2021) Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis. Psychopharmacology 238:1737–1752. https://doi.org/10.1007/s00213-021-05825-8CrossRefPubMed

11.

Ho RCM, Zhang MW (2016) Ketamine as a rapid antidepressant: the debate and implications. BJPsych Adv 22:222–233. https://doi.org/10.1192/apt.bp.114.014274CrossRef

12.

Costi S, Van Dam NT, Murrough JW (2015) Current status of ketamine and related therapies for mood and anxiety disorders. Curr Behav Neurosci Rep 2:216–225. https://doi.org/10.1007/s40473-015-0052-3CrossRefPubMedPubMedCentral

13.

Tully JL, Dahlén AD, Haggarty CJ, Schiöth HB, Brooks S (2022) Ketamine treatment for refractory anxiety: a systematic review. Br J Clin Pharmacol 88:4412–4426. https://doi.org/10.1111/bcp.15374CrossRefPubMed

14.

Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, Beauchamp S (2020) A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009—January 2019. J Affect Disord 277:831–841. https://doi.org/10.1016/j.jad.2020.09.007CrossRefPubMed

15.

Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression. CNS Drugs 26:189–204. https://doi.org/10.2165/11599770-000000000-00000CrossRefPubMedPubMedCentral

16.

Goldstein TR, Merranko J, Rode N, Sylvester R, Hotkowski N, Fersch-Podrat R, Hafeman DM, Diler R, Sakolsky D, Franzen P, Birmaher B (2023) Dialectical behavior therapy for adolescents with bipolar disorder: a randomized clinical trial. JAMA Psychiat 81:15–24. https://doi.org/10.1001/jamapsychiatry.2023.3399CrossRef

17.

James AC, James G, Cowdrey FA, Soler A, Choke A (2015) Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2015:CD004690. https://doi.org/10.1002/14651858.CD004690.pub4CrossRefPubMedPubMedCentral

18.

Oud M, de Winter L, Vermeulen-Smit E, Bodden D, Nauta M, Stone L, van den Heuvel M, Taher RA, de Graaf I, Kendall T, Engels R, Stikkelbroek Y (2019) Effectiveness of CBT for children and adolescents with depression: a systematic review and meta-regression analysis. Eur Psychiatry J Assoc Eur Psychiatr 57:33–45. https://doi.org/10.1016/j.eurpsy.2018.12.008CrossRef

19.

Cook NE, Gorraiz M (2016) Dialectical behavior therapy for nonsuicidal self-injury and depression among adolescents: preliminary meta-analytic evidence. Child Adolesc Ment Health 21:81–89. https://doi.org/10.1111/camh.12112CrossRefPubMed

20.

Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 7:581–601. https://doi.org/10.1016/S2215-0366(20)30137-1CrossRefPubMedPubMedCentral

21.

Dwyer JB, Stringaris A, Brent DA, Bloch MH (2020) Annual research review: defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 61:312–332. https://doi.org/10.1111/jcpp.13202CrossRefPubMedPubMedCentral

22.

Dwyer JB, Bloch MH (2019) Antidepressants for pediatric patients. Curr Psychiatry 18:26-42F

23.

Bali A, Dang AK, Gonzalez DA, Kumar R, Asif S, Bali A, Dang AK, Gonzalez DA, Kumar R, Asif S (2022) Clinical uses of ketamine in children: a narrative review. Cureus 14:e27065. https://doi.org/10.7759/cureus.27065CrossRefPubMedPubMedCentral

24.

Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S (2013) Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord 147:431–436. https://doi.org/10.1016/j.jad.2012.08.040CrossRefPubMed

25.

Kim S, Rush BS, Rice TR (2021) A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Eur Child Adolesc Psychiatry 30:1485–1501. https://doi.org/10.1007/s00787-020-01542-3CrossRefPubMed

26.

Acevedo J, Siegel JA (2022) Neurobiological, behavioral, and cognitive effects of ketamine in adolescents: a review of human and pre-clinical research. Behav Brain Res 435:114049. https://doi.org/10.1016/j.bbr.2022.114049CrossRefPubMed

27.

Meshkat S, Rosenblat JD, Ho RC, Rhee TG, Cao B, Ceban F, Danayan K, Chisamore N, Vincenzo JDD, McIntyre RS (2022) Ketamine use in pediatric depression: a systematic review. Psychiatry Res 317:114911. https://doi.org/10.1016/j.psychres.2022.114911CrossRefPubMed

28.

Di Vincenzo JD, Siegel A, Lipsitz O, Ho R, Teopiz KM, Ng J, Lui LMW, Lin K, Cao B, Rodrigues NB, Gill H, McIntyre RS, Rosenblat JD (2021) The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review. J Psychiatr Res 137:232–241. https://doi.org/10.1016/j.jpsychires.2021.02.058CrossRefPubMed

29.

Ryan K, Hosanagar A (2023) Ketamine use in child and adolescent psychiatry: emerging data in treatment-resistant depression, insights from adults, and future directions. Curr Psychiatry Rep 25:337–344. https://doi.org/10.1007/s11920-023-01432-wCrossRefPubMed

30.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

31.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5:210. https://doi.org/10.1186/s13643-016-0384-4CrossRefPubMedPubMedCentral

32.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898CrossRefPubMed

33.

Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH (2017) Ketamine as a treatment for adolescent depression: a case report. J Am Acad Child Adolesc Psychiatry 56:352–354. https://doi.org/10.1016/j.jaac.2017.01.006CrossRefPubMed

34.

Skala K, Doganay K, Eder H, Mairhofer D, Neubacher K, Plener PL (2023) Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression. Front Psychiatry 14:1118737. https://doi.org/10.3389/fpsyt.2023.1118737CrossRefPubMedPubMedCentral

35.

Weber G, Yao J, Binns S, Namkoong S (2018) Case report of subanesthetic intravenous ketamine infusion for the treatment of neuropathic pain and depression with suicidal features in a pediatric patient. Case Rep Anesthesiol 2018:9375910. https://doi.org/10.1155/2018/9375910CrossRefPubMedPubMedCentral

36.

Easterly CW, Taylor R (2023) Ketamine augmentation of electroconvulsive therapy in an adolescent patient with suicidal ideation, disordered eating, and type 1 diabetes mellitus: a case report. J ECT 39:63–64. https://doi.org/10.1097/YCT.0000000000000878CrossRefPubMed

37.

Jerath AU, Oldak SE, Parrish MS, Zaydlin M, Martin S, Brown K, Cara V, Coffey BJ (2023) Ketamine and transcranial magnetic stimulation in an adolescent with treatment-resistant depression. J Child Adolesc Psychopharmacol 33:297–303. https://doi.org/10.1089/cap.2023.29245.bjcCrossRefPubMed

38.

Sampath H, Sharma I, Dutta S (2016) Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder. Asia-Pac Psychiatry Off J Pac Rim Coll Psychiatr 8:98–101. https://doi.org/10.1111/appy.12220CrossRef

39.

Zarrinnegar P, Kothari J, Cheng K (2019) Successful use of ketamine for the treatment of psychotic depression in a teenager. J Child Adolesc Psychopharmacol 29:472–473. https://doi.org/10.1089/cap.2019.0028CrossRefPubMed

40.

Marshall R, Valle K, Sheridan D, Kothari J (2023) Ketamine for treatment-resistant depression and suicidality in adolescents: an observational study of 3 cases. J Clin Psychopharmacol. https://doi.org/10.1097/JCP.0000000000001730CrossRefPubMed

41.

Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B (2018) Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol 28:437–444. https://doi.org/10.1089/cap.2018.0030CrossRefPubMedPubMedCentral

42.

Keeler JL, Treasure J, Himmerich H, Brendle M, Moore C, Robison R (2023) Case report: intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa. Front Psychiatry 14:1181447CrossRefPubMedPubMedCentral

43.

Wolfson PE, Andries J, Ahlers D, Whippo M (2023) Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses. Front Psychiatry 14:1141988. https://doi.org/10.3389/fpsyt.2023.1141988CrossRefPubMedPubMedCentral

44.

Faria-Guimarães D, Vieira F, Souza-Marques B, Silva SS, Bandeira ID, Souza LS, Alves-Pereira R, Fontes M, Mello RP, Leal GC, Cardoso TA, Kapczinski F, Lacerda ALT, Sampaio AS, Quarantini LC (2022) Letter to the editor: antidepressant and antisuicidal effects of esketamine in adolescents with major depressive disorder and suicidal ideation: a case series. J Child Adolesc Psychopharmacol 32:366–367. https://doi.org/10.1089/cap.2022.0013CrossRefPubMed

45.

Amel AK, Hosseini F (2023) A comparison of the anti-anxiety effects of oral ketamine and fluvoxamine in children with separation anxiety disorder manifesting as school refusal. Adv Biomed Res 12:110. https://doi.org/10.4103/abr.abr_388_22CrossRef

46.

Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH (2021) Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry 178:352–362. https://doi.org/10.1176/appi.ajp.2020.20010018CrossRefPubMed

47.

Zhou Y, Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, Ye Y, Hu Z, Chao Z, Ning Y (2023) Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. J Am Acad Child Adolesc Psychiatry S0890–8567(23):00373–00378. https://doi.org/10.1016/j.jaac.2023.05.031CrossRef

48.

Lineham A, Avila-Quintero VJ, Bloch MH, Dwyer J (2023) The relationship between acute dissociative effects induced by ketamine and treatment response in adolescent patients with treatment-resistant depression. J Child Adolesc Psychopharmacol 33:20–26. https://doi.org/10.1089/cap.2022.0086CrossRefPubMed

49.

Lineham A, Avila-Quintero VJ, Bloch MH, Dwyer J (2024) Exploring predictors of ketamine response in adolescent treatment-resistant depression. J Child Adolesc Psychopharmacol. https://doi.org/10.1089/cap.2023.0047CrossRefPubMed

50.

Roy AV, Thai M, Klimes-Dougan B, Westlund Schreiner M, Mueller BA, Albott CS, Lim KO, Fiecas M, Tye SJ, Cullen KR (2021) Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: preliminary evidence in adolescents with treatment-resistant depression. J Psychopharmacol Oxf Engl 35:168–177. https://doi.org/10.1177/0269881120928203CrossRef

51.

Thai M, Başgöze Z, Klimes-Dougan B, Mueller BA, Fiecas M, Lim KO, Albott CS, Cullen KR (2020) Neural and behavioral correlates of clinical improvement to ketamine in adolescents with treatment resistant depression. Front Psychiatry 11:820. https://doi.org/10.3389/fpsyt.2020.00820CrossRefPubMedPubMedCentral

52.

Lan X, Wang C, Zhang F, Liu H, Fu L, Li W, Ye Y, Hu Z, Mai S, Ning Y, Zhou Y (2023) Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression. Gen Psychiatry 36:e101007. https://doi.org/10.1136/gpsych-2023-101007CrossRef

53.

Lan X, Wang C, Zhang F, Liu H, Li W, Ye Y, Hu Z, Mai S, Ning Y, Zhou Y (2023) Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial. Child Adolesc Psychiatry Ment Health 17:108. https://doi.org/10.1186/s13034-023-00647-2CrossRefPubMedPubMedCentral

54.

Anderson DJ, Zhou J, Cao D, McDonald M, Guenther M, Hasoon J, Viswanath O, Kaye AD, Urits I (2022) Ketamine-induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug. Health Psychol Res 10:38247. https://doi.org/10.52965/001c.38247CrossRefPubMedPubMedCentral

55.

Cisler JM, Olatunji BO (2012) Emotion regulation and anxiety disorders. Curr Psychiatry Rep 14:182–187. https://doi.org/10.1007/s11920-012-0262-2CrossRefPubMedPubMedCentral

56.

Joormann J, Gotlib IH (2010) Emotion regulation in depression: relation to cognitive inhibition. Cogn Emot 24:281–298. https://doi.org/10.1080/02699930903407948CrossRefPubMedPubMedCentral

57.

Ayık B, Baş A, Usta Sağlam NG, İzci F (2023) The relationship between emotional dysregulation, alexithymia and somatization in patients with bipolar disorder. Alpha Psychiatry 24:15–21. https://doi.org/10.5152/alphapsychiatry.2023.22974CrossRefPubMedPubMedCentral

58.

Berner JE (2007) Intranasal ketamine for intermittent explosive disorder: a case report. J Clin Psychiatry 68:1305CrossRefPubMed

59.

Donoghue AC, Roback MG, Cullen KR (2015) Remission from behavioral dysregulation in a child with PTSD after receiving procedural ketamine. Pediatrics 136:e694–e696. https://doi.org/10.1542/peds.2014-4152CrossRefPubMed

60.

Kowalski JM, Kopec KT, Lavelle J, Osterhoudt K (2017) A novel agent for management of agitated delirium: a case series of ketamine utilization in the pediatric emergency department. Pediatr Emerg Care 33:e58–e62. https://doi.org/10.1097/PEC.0000000000000578CrossRefPubMed

61.

Yavi M, Lee H, Henter ID et al (2022) Ketamine treatment for depression: a review. Discov Ment Health 2:9. https://doi.org/10.1007/s44192-022-00012-3CrossRefPubMedPubMedCentral

62.

Vankawala J, Naples G, Avila-Quintero VJ, Ramírez KL, Flores JM, Bloch MH, Dwyer JB (2021) Meta-analysis: hemodynamic responses to sub-anesthetic doses of ketamine in patients with psychiatric disorders. Front Psychiatry 12:549080. https://doi.org/10.3389/fpsyt.2021.549080CrossRefPubMedPubMedCentral

63.

Veraart JKE, Smith-Apeldoorn SY, Spijker J, Kamphuis J, Schoevers RA (2021) Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review. J Clin Psychiatry 82:20r13459. https://doi.org/10.4088/JCP.20r13459CrossRefPubMed

64.

An D, Wei C, Wang J, Wu A (2021) Intranasal ketamine for depression in adults: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. Front Psychol 12:648691. https://doi.org/10.3389/fpsyg.2021.648691CrossRefPubMedPubMedCentral

65.

Bahji A, Zarate CA, Vazquez GH (2021) Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol 24:535–541. https://doi.org/10.1093/ijnp/pyab023CrossRefPubMedPubMedCentral

66.

Marchi M, Magarini FM, Galli G, Mordenti F, Travascio A, Uberti D, De Micheli E, Pingani L, Ferrari S, Galeazzi GM (2022) The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: a systematic review and meta-analysis. Front Neurosci 16:1011103. https://doi.org/10.3389/fnins.2022.1011103CrossRefPubMedPubMedCentral

67.

Corwell BN, Motov SM, Davis NL, Kim HK (2022) Novel uses of ketamine in the emergency department. Expert Opin Drug Saf 21:1009–1025. https://doi.org/10.1080/14740338.2022.2100883CrossRefPubMed

68.

Chubbs B, Wang J, Archer S, Chrenek C, Khullar A, Wolowyk M, Swainson J (2022) A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: a preliminary evaluation of real world addictive potential. Front Psychiatry 13:1016439CrossRefPubMedPubMedCentral

69.

Joneborg I, Lee Y, Di Vincenzo JD, Ceban F, Meshkat S, Lui LMW, Fancy F, Rosenblat JD, McIntyre RS (2022) Active mechanisms of ketamine-assisted psychotherapy: a systematic review. J Affect Disord 315:105–112. https://doi.org/10.1016/j.jad.2022.07.030CrossRefPubMed

70.

Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B (2023) Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med 388:2315–2325. https://doi.org/10.1056/NEJMoa2302399CrossRefPubMed

71.

Anderson IM, Blamire A, Branton T, Brigadoi S, Clark R, Downey D, Dunn G, Easton A, Elliott R, Elwell C, Hayden K, Holland F, Karim S, Lowe J, Loo C, Nair R, Oakley T, Prakash A, Sharma PK, Williams SR, McAllister-Williams RH (2017) Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (ketamine-ECT study). NIHR Journals Library, Southampton

72.

Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, Nierenberg AA (2009) STAR*D: revising conventional wisdom. CNS Drugs 23:627–647. https://doi.org/10.2165/00023210-200923080-00001CrossRefPubMed

73.

Gabriel FC, Stein AT, Melo DO, Fontes-Mota GCH, Dos Santos IB, Rodrigues CS, Dourado A, Rodrigues MC, Fráguas R, Florez ID, Correia DT, Ribeiro E (2023) Guidelines’ recommendations for the treatment-resistant depression: a systematic review of their quality. PLoS ONE 18:e0281501. https://doi.org/10.1371/journal.pone.0281501CrossRefPubMedPubMedCentral

Title: Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review
Authors: Alisha M. Bruton
Dalton G. Wesemann
Taryn A. Machingo
Gop Majak
Jeanette M. Johnstone
Rebecca D. Marshall
Publication date: 16-05-2024
Publisher: Springer Berlin Heidelberg
Keywords: Ketamine
Mood Disorders
Affective Disorder
Anxiety
Esketamine
Esketamin
Midazolam
Suicide
Suicide
Suicidality
Published in: European Child & Adolescent Psychiatry
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-024-02458-y

2024 ESC Congress

Springer Medicine

Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review

Abstract

2024 ESC Congress

Springer Medicine

Abstract

Please log in to get access to this content